BMAL1 and breast carcinoma: Similarly, BMAL1 knockout increased the sensitivity of non-tumorigenic human breast epithelial MCF10A cells and metastatic human breast cancer MDA-MB-231 cells to cisplatin and doxorubicin while enhancing the invasive capacity of MDA-MB-231 cells, which confirms that disruption of BMAL1 gene may have opposing carcinogenic effects [58].